This story has been corrected from a previous version that incorrectly referred to Sirna Therapeutics instead of Alnylam. RNAi News regrets the error.
As might have been expected, the need for potent siRNAs for RNAi research and effective delivery methods for therapeutics were two of the underlying themes of many of the presentations at the Nucleic Acid World Summit in Boston this week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
